Business Trends– category –
-
REPROCELL Develops Hypoimmune iPSC Engineering with AI-Designed CRISPR for Off-the-Shelf Cell Therapies
REPROCELL Japan Overview REPROCELL announced a method to develop hypoimmune iPSCs using AI-designed CRISPR, leveraging its StemEdit gene-editing platform. This approach targets key immune recognition genes like B2M and CIITA to create un... -
Human Continuum Closes Over $5 Million in Seed Round Funding to Advance Exosome-Based Therapeutic Longevity Platform Development
GlobeNewswire (Human Continuum Inc.) USA Overview Human Continuum Inc. successfully completed a $5.13 million seed funding round to accelerate the development of its exosome-based therapeutic and diagnostic platform across longevity, ort... -
Novartis and Orionis Biosciences Enter Strategic Collaboration for Molecular Glue Discovery in Up to $1.4 Billion Deal
BioBucks Biotech BD&L Tracker USA Overview Novartis announced a strategic collaboration with Orionis Biosciences to leverage Orionis' AI-driven "Allo-Glue™" platform across multiple challenging therapeutic targets. The deal includes a $4... -
AmMax Bio Licenses Lonza’s Conjugation and Linker-Payload Technologies for ADC Program AMB-104
The Pharma Letter USA Overview AmMax Bio announced a non-exclusive licensing agreement with Lonza, a leading CDMO, to utilize Lonza's conjugation and linker-payload technologies. This collaboration aims to support the development of AmMa... -
Cartesian Therapeutics and WestGene Biopharma Announce Strategic Licensing Agreement to Accelerate In Vivo CAR T Platform Development for Autoimmune Diseases
BioSpace (Cartesian Therapeutics) USA Overview Cartesian Therapeutics announced a strategic licensing agreement with WestGene Biopharma to accelerate the development of novel in vivo Chimeric Antigen Receptor T-cell (CAR-T) therapies for... -
ENCell Secures US Clinical Manufacturing Contract for Ingenium Therapeutics’ NK Cell Therapy Gengleucel, Expanding Global CDMO Operations
Bio South Korea Overview ENCell, a South Korean CDMO specializing in cell and gene therapy, has signed an additional CMO contract with Ingenium Therapeutics for the manufacturing of clinical trial materials for its NK cell therapy candid... -
Alcami Expands CDMO Packaging Capabilities with Tjoapack Acquisition, Strengthening Cell and Gene Therapy Supply Chain
North Carolina Biotechnology Center USA Overview Alcami Corporation, a Contract Development and Manufacturing Organization (CDMO), has significantly expanded its packaging capabilities through the acquisition of global contract packaging... -
Made Scientific and Pluristyx Form Strategic Partnership to Integrate iPSC Technology and Expand Cell Therapy Manufacturing CDMO Services
BioPharm International USA Overview Made Scientific announced a strategic partnership with Pluristyx, an iPSC technology platform provider, to integrate iPSC technology into its cell therapy CDMO services. This collaboration will provide... -
FUJIFILM Cellular Dynamics Opens New iPSC Manufacturing Facility and Reorganizes Life Sciences Leadership to Accelerate Cell Therapy and iPSC Business Expansion
FUJIFILM Cellular Dynamics / Indian Pharma Post Japan Overview FUJIFILM Cellular Dynamics announced the opening of its new headquarters and iPSC development and manufacturing facility in Madison, tripling its iPSC-based research product ... -
FDA Issues Draft Guidance to Streamline Regulatory Submissions for Cell and Gene Therapy Products by Leveraging Prior Knowledge
Pharmuni USA Overview The U.S. FDA has released new draft guidance aimed at accelerating the development of cell and gene therapy products for rare diseases. This guidance permits developers to leverage existing scientific, manufacturing...
